Document is current
Any future updates will be listed below
-
Authors
Konczal, Laura
Enns, Gregory M.
Gropman, Andrea L.
Garcia, Daniel
Merritt II, J. Lawrence
Wilkening, Greta
- License Information
-
More Information
Article History
Received: 29 October 2025
Accepted: 9 February 2026
First Online: 13 March 2026
Declarations
:
: Laura Konczal has been a site principal investigator (PI) for the Ultragenyx-sponsored 301OTC02 and DTX301-CL301 clinical trials, as well as the Urea Cycle Disorders Consortium (UCDC) 5101 and 5121 longitudinal studies. Gregory M. Enns has been a site PI for the Moderna mRNA-3927 and mRNA-3705 clinical trials; a data monitoring committee member for clinical trials by Abliva, Amicus, Astellas, BioMarin, Paradigm, Passage Bio, Regenxbio, and UCB; and a consultant for M6P and Mitsubishi Tanabe. Andrea L. Gropman has been a PI for UCDC; a site PI for the North American Mitochondrial Disease Consortium; and educational podcasts for Baylor Miraca Genetics Laboratories. Daniel Garcia and J. Lawrence Merritt II are employees of and shareholders in Ultragenyx Pharmaceutical Inc. Greta Wilkening has been a site co-PI for the UCDC 5101 and 5121 longitudinal studies.
